HighLife Overview

  • Founded

  • 2010

Founded
  • Status

  • Private

  • Employees

  • 70

Employees
  • Latest Deal Type

  • Series B

  • Latest Deal Amount

  • $36.5M

  • Investors

  • 8

HighLife General Information

Description

Developer of a novel transcatheter replacement system designed to help in the treatment of mitral regurgitation. The company's system targets optimal treatment outcomes as it can be delivered through a transseptal passage via the femoral vein in a reversible manner, and self-locates inside the native annulus, enabling physicians to reduce trauma to the patients while caring out severe heart surgery procedures.

Contact Information

Website
www.highlifemedical.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
  • 100 avenue de Suffren
  • 75015 Paris
  • France

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HighLife Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 10-Jan-2019 $36.5M 0000 000.00 Completed Generating Revenue
3. Later Stage VC (Series A) 29-Jul-2017 000.00 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series A) 26-Nov-2012 $5.39M $12.3M Completed Generating Revenue
1. Early Stage VC 09-Nov-2012 $6.93M $6.93M 000.00 Completed Generating Revenue
To view HighLife’s complete valuation and funding history, request access »

HighLife Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
B Shares 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
A2 Shares 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
A Shares 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
A Shares 1,634,241 $0.011407 $2.93 $2.93 1x $2.93 3.02%
Ordinary 450,770 $0.011407 $2.93 $2.93 1x $2.93 0.83%
To view HighLife’s complete cap table history, request access »

HighLife Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a novel transcatheter replacement system designed to help in the treatment of mitral regurgitation. The com
Therapeutic Devices
Paris, France
70 As of 2023
0000
00.00 0000-00-00
00000000000 0000

000000

et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ulla
00000000000 0000000
Tel Aviv, Israel
00 As of 0000
000.00
0000000000 0 000.00

000000

ip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
00000000000 0000000
Milan, Italy
00 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

HighLife Competitors (19)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Coramaze Technologies Venture Capital-Backed Tel Aviv, Israel 00 000.00 0000000000 0 000.00
0000000000 Venture Capital-Backed Milan, Italy 00 000.00 00000000000 000.00
0000000 0000000000 Venture Capital-Backed Kirkland, WA 00 00000 00000000000 00000
0000000 Venture Capital-Backed Herzliya, Israel 00 000.00 0000000000 0 000.00
000000 Venture Capital-Backed Eagan, MN 00 0000 000000000 - 0000
You’re viewing 5 of 19 competitors. Get the full list »

HighLife Patents

  • 174

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 25

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

HighLife Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021203899-A1 Transcatheter valve prosthesis and method for implanting the same Pending 26-Jun-2020 0000000000
US-20210401572-A1 Transcatheter valve prosthesis and method for implanting the same Pending 26-Jun-2020 0000000000 00
AU-2020420173-A1 Transcatheter valve prosthesis Pending 07-Jan-2020 0000000000
CA-3166351-A1 Transcatheter valve prosthesis Pending 07-Jan-2020 0000000000
EP-4087520-A1 Transcatheter valve prosthesis Pending 07-Jan-2020 A61F2/2418
To view HighLife’s complete patent history, request access »

HighLife Executive Team (4)

Name Title Board Seat Contact Info
Georg Börtlein Co-Founder, Chief Executive Officer, President & Board Member
Steve Backer Chief Operating Officer
Martin Rothman Chief Medical Officer & Board Member
You’re viewing 3 of 4 executive team members. Get the full list »

HighLife Board Members (10)

Name Representing Role Since
Anne Osdoit Sofinnova Partners Board Observer 000 0000
Antoine Papiernik Sofinnova Partners Board Member 000 0000
Arnd Kaltofen Ehmann MD VI Partners Board Observer 000 0000
Casey Tansey US Venture Partners Board Member 000 0000
Jose Gordo Self Chairman of the Board 000 0000
You’re viewing 5 of 10 board members. Get the full list »

HighLife Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HighLife Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Andera Partners PE/Buyout Minority 000 0000 000000 0
Jose Gordo Angel (individual) Minority 000 0000 000000 0
Sectoral Asset Management Asset Manager Minority 000 0000 000000 0
US Venture Partners Venture Capital Minority 000 0000 000000 0
VI Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial